Group sales of the first nine months of FY 2012 increased by 4.4 percent

Offenburg, 01 November 2012 – In the first nine months of FY 2012 MEDICLIN Aktiengesellschaft (MediClin) has achieved Group sales of EUR 383.8 mill. (9 M 2011: EUR 367.7 mill.) which were EUR 16.1 mill. or 4.4 % higher than in the same period of last year. EUR 13.6 mill. of the sales increase were attributed to the post-acute segment. Sales of the acute segment were EUR 150.8 mill. (9 M 2011: EUR150.7 mill.) thus on previous year’s level, sales of the business field nursing care increased by EUR 1.0 mill. up to EUR 9.8 mill. (9 M 2011: EUR 8.8 mill.).

The Group operating result of EUR 6.2 mill. (9 M 2011: EUR 7.0 mill.) was EUR 0.8 mill. lower than in the same period of last year. The previous year’s value contained aperiodic releases of provisions in the amount of EUR 2.9 mill. Adjusted by these special effects the Group operating result for the first nine months of FY 2012 would be EUR 2.0 mill. higher than the previous year’s value.

Less other operating income in the amount of EUR 3.1 mill. as well as additional expenses in the amount of in total EUR 13.8 mill. stood against the increase in sales of EUR 16.1. mill. Of the additional expenses EUR 9.0 mill. applied to staff costs, EUR 3.4 mill to other operating expenses, EUR 0,8 mill. to raw materials and consumables used and EUR 0.7 mill. to depreciation and amortisation.
The Group result attributable to shareholders of MediClin amounted to EUR 2.4 mill. (9 M 2011: EUR 0.6 mill.). The un-/diluted earnings per share for the first nine months of FY 2012 amounted to EUR 0.05 (9 M 2011: EUR 0.01).

Post-acute segment clearly above previous year’s figures
The post-acute segment result of EUR 4.6 mill. has improved significantly in the nine-month comparison. The determining factors were the noticeable sales increase of EUR 13.6 mill. and an only under-proportional increase in expenses.
For the same period with sales nearly unchanged and despite increased numbers of nursing days and cases the acute segment result shows a decrease of EUR 5.9 mill. Especially the 4.8 % higher staff costs as well as the 8.5 % higher other operating expenses – here in particular maintenance costs – did burden the result. 
 

Investments are still on a high level
In the reporting period, investments in non-current assets were made totalling a gross amount of EUR 19.8 mill. (9 M 2011: EUR 24.0 mill.). As of 30 September 2012 cash and cash equivalents were EUR 27.5 mill. (31.12.2011: EUR 41.3 mill.). The equity ratio was 51.9 %

Outlook
The Management Board expects sales to rise and earnings to develop soundly in the financial year 2012 provided there are no fundamental changes to the conditions underlying the industry and to the referral behaviour of the coverage providers.

The interim report as of 30 September 2012 will be available as of 14 November 2012 under www.mediclin.de in German and English.

About MediClin AG (Ticker: MED; WKN: 659 510)
MediClin AG is a nation-wide clinic operator and large provider of services in the area of Psycho- and Neuro-sciences as well as Orthopaedic. With 34 clinics and 7 nursing care facilities and 11 Medizinische Versorgungs-zentren (medical care units) in 11 federal states MediClin has a total capacity of approxi¬mately 8,100 beds. MediClins’ facilities include acute care clinics, i.e., general hospitals, special treatment facilities, specialised hospitals and clinics for post-acute treatment and medical rehabilitation. MediClin has approximately 8,400 employees.